Nuclear Medicines are primarily drugs that contain radioactive elements for radionuclide-emitting ionizing radiations. Their core application lies in the diagnosis and treatment of various diseases that conventional medicines fail to achieve. Radiopharmaceuticals are unique as they are used to directly target specific organs sites in the body where the drug can emit radiations. These radiations are then captured by gamma cameras placed in proximity of the patient. The radiation dose in these pharmaceuticals is kept as low as possible to avoid the side effects of radiation exposure.
This report elaborates the market size, market characteristics, and market growth of the Nuclear Medicine-Radiopharmaceuticals industry, and breaks down according to the type, application, and consumption area of Nuclear Medicine-Radiopharmaceuticals. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Nuclear Medicine-Radiopharmaceuticals in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Nuclear Medicine-Radiopharmaceuticals market covered in Chapter 13:
Alliance Medical
Siemens Healthcare
Lantheus Medical Imaging Inc
Avid Radiopharmaceuticals
Actinium Pharmaceuticals Inc
Advanced Medical Isotope Corporation
Nordion, Inc.
Peregrine Pharmaceuticals, Inc.
GE Healthcare
Alseres Pharmaceuticals, Inc
Immunomedics, Inc.
Jubilant Pharma
Ion Beam Applications S.A
Mallinckrodt Pharmaceuticals
Medi-Radiopharma Ltd
Triad Isotopes, Inc.
Bracco Imaging S.p.A
Cardinal Health, Inc
Bayer HealthCare Medical Care
Positron Corporation
In Chapter 6, on the basis of types, the Nuclear Medicine-Radiopharmaceuticals market from 2015 to 2025 is primarily split into:
Diagnostic Medicine
Therapeutic Medicine
In Chapter 7, on the basis of applications, the Nuclear Medicine-Radiopharmaceuticals market from 2015 to 2025 covers:
SPECT
PET
Therapeutic
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
2019
This report elaborates the market size, market characteristics, and market growth of the Nuclear Medicine-Radiopharmaceuticals industry, and breaks down according to the type, application, and consumption area of Nuclear Medicine-Radiopharmaceuticals. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Nuclear Medicine-Radiopharmaceuticals in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Nuclear Medicine-Radiopharmaceuticals market covered in Chapter 13:
Alliance Medical
Siemens Healthcare
Lantheus Medical Imaging Inc
Avid Radiopharmaceuticals
Actinium Pharmaceuticals Inc
Advanced Medical Isotope Corporation
Nordion, Inc.
Peregrine Pharmaceuticals, Inc.
GE Healthcare
Alseres Pharmaceuticals, Inc
Immunomedics, Inc.
Jubilant Pharma
Ion Beam Applications S.A
Mallinckrodt Pharmaceuticals
Medi-Radiopharma Ltd
Triad Isotopes, Inc.
Bracco Imaging S.p.A
Cardinal Health, Inc
Bayer HealthCare Medical Care
Positron Corporation
In Chapter 6, on the basis of types, the Nuclear Medicine-Radiopharmaceuticals market from 2015 to 2025 is primarily split into:
Diagnostic Medicine
Therapeutic Medicine
In Chapter 7, on the basis of applications, the Nuclear Medicine-Radiopharmaceuticals market from 2015 to 2025 covers:
SPECT
PET
Therapeutic
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.